SEP 11, 2018 09:42 PM PDT

Widely-Used Drug Contributed To Skin Cancer

WRITTEN BY: Nouran Amin

Credit:  MIT

In a research study at the University of Dundee, Queen Mary University of London and the Wellcome Sanger Institute, a drug, by the name of azathioprine, which is used to treat inflammatory bowel disease (IBD), arthritis and vasculitis as well as preventing organ rejection in transplant patients, has been identified as a contributor the development of skin cancer.

Published in Nature Communications, the research identified a `strong case for an association' between azathioprine and a mutation found in a common form of skin cancer known as cutaneous squamous cell carcinoma (cSCC). Previously, it was known that azathioprine leads to a heightened photosensitivity to UVA light. Such sensitivity is believed to be the key behind its contribution to skin cancers. The study found that the use of azathioprine leaves a ‘molecular fingerprint’ in skin cancers, implicating it in cSCC. "We recommend all physicians give appropriate advice on UVA avoidance including year-round sun protection for their patients on azathioprine,” explains Professor of Dermatology--Charlotte Proby in the School of Medicine at Dundee.

Credit: Ctdermgroup.com

However, the research team is not necessarily promoting the withdrawal of azathioprine. "As with all medications the risks must be balanced against the benefits, particularly with the need to treat potentially life-threatening diseases with an effective drug," explains Proby. “It is important that sun protection, skin surveillance and early diagnosis/lesion removal are part of the routine management of patients on azathioprine."

cSCC is a commonly diagnosed skin cancer. "It's important to protect your skin from the sun when it's strong, especially if you burn easily or are taking medications which make you more sun-sensitive. The most effective protection is to spend time in the shade and cover up with a hat, long-sleeved top, and sunglasses. For the bits you can't cover, use sunscreen with at least 4 stars and SPF 15 or higher for protection against both UVA and UVB rays,” says Sarah Lowes of Cancer Research UK.

The research also revealed the molecular nature of cSCC which highlighted the potential targets that may be developed for future treatments.

Source: University of Dundee, Nature Communications

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JUN 20, 2018
Drug Discovery
JUN 20, 2018
How Rheumatoid Arthritis Drugs Affect Mental Health
Rheumatoid arthritis (RA) is an autoimmune disease where the immune system of an affected individual attacks its own body, in this case the joints. Mental ...
JUN 27, 2018
Drug Discovery
JUN 27, 2018
Efficacy of The 24 Hour Killing Flu Drug 'Xofluza' Examined
Xofluza, the recent 24-hour killing flu drug that was developed by the Japanese pharmaceutical company Shionogi and approved for clinical use in Japan, is ...
JUL 12, 2018
Infographics
JUL 12, 2018
3D Imaging Advantage
Learn about the advantages and the technology behind 3D cellular image acquisition and analysis with this infographic from Molecular Devices....
JUL 24, 2018
Drug Discovery
JUL 24, 2018
Therapeutic Target For Kidney Cancers
Researchers at Lineberger Comprehensive Cancer Center in University of North Carolina revealed a therapeutic target for kidney cancers that share a common ...
AUG 15, 2018
Drug Discovery
AUG 15, 2018
Experimental Drug May Treat The Chronic Itch
Investigators at the University of Zurich have discovered a new approach that treats the chronic itch thanks to two receptors in the spinal cord and the ri...
AUG 20, 2018
Drug Discovery
AUG 20, 2018
Drug Seeks To Prevent a Painful Side-Effect
Many patients with head, neck, nasal, and oral cancers are treated with radiations. Unfortunately, such treatment leaves patients with a painful side-effec...
Loading Comments...